A recent study sheds light on a biological mechanism that may help slow liver deterioration and reduce inflammation.
Researchers, co-led by Cedars-Sinai, have identified an enzyme that could help protect the liver from the damage associated with the progression of the most common form of liver disease. The findings of this preclinical study, published in the journal *Nature Metabolism*, suggest that they could potentially support new strategies for preventing serious liver injury and the progression toward liver failure.
A Condition Affecting 100 Million Americans
According to the American Liver Foundation, an estimated 100 million people in the United States suffer from metabolic dysfunction-associated fatty liver disease. In 20% to 25% of these cases, the condition progresses to metabolic dysfunction-associated steatohepatitis (MASH)—a more severe form characterized by excess fat, inflammation, cell damage, and fibrosis.
Why Is the Advanced Stage Difficult to Treat?
Currently, treatment relies primarily on lifestyle changes aimed at limiting further liver damage. Although some medications are available, therapeutic options remain limited, and to date, there is no definitive cure for this condition.
Previous research has indicated that damage to mitochondria—the energy-producing centers within cells—may contribute to the development and progression of the disease. In a new multicenter study, researchers at Cedars-Sinai discovered that levels of an enzyme called "UBE2N" decrease in liver cells as a disease progresses.
A Hidden Guardian of the Liver
Dr. Ekihiro Seki, a professor of medicine and biomedical sciences at Cedars-Sinai and a co-corresponding author of the study, explains that the enzyme appears to protect the liver from disease-related inflammation and damage by assisting in the removal of damaged mitochondria and supporting the breakdown of fats. He adds that when levels of this enzyme dropped, an increase in damaged cells and greater liver injury were observed.
A Potential Therapeutic Target
The researchers subsequently restored the enzyme’s levels in the livers of laboratory mice, observing a reduction in fat accumulation, inflammation, and fibrosis. These findings suggest that the enzyme could serve as a potential therapeutic target to prevent fatty liver disease from progressing to an inflammatory stage.
Next Steps
Dr. Shelly Lu, chair of the Division of Digestive and Liver Diseases at Cedars-Sinai, views the identification of this enzyme’s role in regulating mitochondria within the liver as a significant advancement in the understanding of fatty liver diseases.
She notes that future studies could investigate whether enhancing this protective pathway might complement existing treatments, identify which patients would benefit most, and lead to new therapeutic approaches to prevent the disease from advancing to more severe stages. It should be noted that these findings are derived from an animal study and have not yet been tested in humans.
Leave a Comment